Category: Drug Safety Alerts
-
New Birth Control Patch Warnings In Canada About Being Overweight, Sauna Or Whirlpool Heat
No Similar Changes To Ortho Evra Label In U.S. As Of Early December 2006 On November 23, 2006 Health Canada released a drug safety alert — which consisted of a so-called "Dear Doctor" letter…
-
David Graham’s NEJM Letter Concerning Sanofi-Aventis Antibiotic Ketek
Suggests That Reports Of Acute Liver Failure Support A Ketek Recall A November 22, 2006 Reuters article by Susan Heavey reports on the latest development as regards the continuing controversy surrounding Ketek (telithromycin), an…
-
Amount Of Epogen And Procrit Given To Patient Tripled Since Early ’90s
Higher Levels Of Popular Anemia Drugs May Increase Risk Of Heart Problems And Death The most recent discussion about safety issues surrounding the anemia drug epoetin — sold by Amgen as Epogen, sold by…
-
Is The End Near For Sanofi-Aventis Antibiotic Ketek?
December 2006 FDA Meeting Will Focus On Side Effect Risks, While Fraud Investigation Continues A November 14, 2006 Associated Press (AP) article was the first to report that in December 2006 the FDA will…
-
Case Reports: Serious Blood Sugar Problems In Patients Taking Tequin
Article Finds Tequin Is "Probable Cause" of Hyperglycemia And Hypoglycemia, Or Dysglycemia, In Most Of Subject Cases There is a Case Reports article concerning Tequin (gatifloxacin) causing serious blood-sugar problems, or dysglycemia, in the…
-
Natrecor: Is Controversial J&J Heart Failure Drug Harmful Or Harmless?
Scios Announces Study To Address Safety Issues But Results Not Expected For Several Years In the October 1, 2006 issue of the medical journal Pharmacotherapy is an article which emphasizes the need to resolve…
-
New Warning About Severe Liver Problems Due To Ketek
Hepatotoxicity Risks Noted In September 2006 "Dear Doctor" Letter On October 4, 2006 Health Canada issued a MedEffect alert to let doctors and patients know that the drug company Sanofi-aventis Canada is updating its…
-
Some Recommendations To Reduce Serious Adverse Drug Reactions In The U.S. (Part of Series: ADRs in US)
Part Three: Medication Errors Can Be Reduced By Better Prescribing Methods In our first part of this series, we looked at the extent of serious adverse drug reactions (ADRs) in the U.S., and in…
-
Preventing Serious Adverse Drug Reactions In The U.S. (Part of Series: ADRs in US)
Part Two: FDA-MIT Database Project Should Improve Drug-safety Monitoring In our first part to this series, we took a look at the extent of serious adverse drug reactions (ADRs) in the U.S. In this…